Melbourne, April 28, 2026, 06:08 AEST
CSL Limited has pushed its on-market buyback — purchases of its own shares through normal exchange trading — past 6 million shares, keeping capital returns in focus while investors test whether the Australian biotech’s battered stock has found a floor. An ASX notice dated Monday showed the company bought 86,383 shares on the previous trading day for A$11.2 million, taking total shares repurchased to 6,084,879 and total consideration to about A$1.024 billion; CSL has said the program can buy back up to US$750 million of ordinary shares.
The timing matters. CSL shares closed at A$131.82 on Monday, up 1.4%, but remained just above Friday’s 52-week low of A$127.75 after a sharp selloff last week; the day’s range was A$129.61 to A$132.21, price data showed.
The pressure came after the Pentagon said U.S. military personnel would no longer be required to receive the flu vaccine. Defense Secretary Pete Hegseth said the mandate was being scrapped; Reuters reported that Sanofi, CSL Seqirus, GSK and AstraZeneca were among vaccine makers sought for comment after the policy change.
For CSL, that policy shift landed on an already weak part of the story. Reuters reported that the U.S. is CSL’s largest revenue source and that Seqirus, its vaccines business, generated about $2.17 billion in revenue in fiscal 2025; Marc Jocum at GlobalXETFs said the Pentagon move added pressure at “the worst possible time,” while Vantage Markets analyst Hebe Chen pointed to slowing earnings momentum and a confidence gap in strategy. Reuters
The half-year accounts explain why the market has been unforgiving. CSL in February reported total revenue of US$8.3 billion for the six months to Dec. 31, down 4% in constant currency, while underlying NPATA — net profit after tax excluding acquired intellectual-property amortisation and major one-offs — fell 7% to US$1.9 billion; reported net profit fell 81% to US$401 million. Chief Financial Officer Ken Lim said CSL was “not satisfied” with performance.
Seqirus was not a clean offset. The company said the unit’s revenue was US$1.6 billion in the first half, down 2%, even as global seasonal influenza sales rose 1% despite lower U.S. immunisation rates; FLUAD sales rose 6%, but FLUCELVAX sales slipped 1%.
The buyback also sits alongside a leadership reset. CSL appointed Gordon Naylor as interim CEO and managing director from Feb. 11 after Paul McKenzie retired; Naylor previously served as the company’s chief financial officer and president of Seqirus, and Chair Brian McNamee said he had “full authority” during the interim period.
U.S. policy risk has not disappeared. CSL told the ASX on April 7 that its initial view was that most U.S. product sales would not face planned pharmaceutical tariffs under Section 232 of the Trade Expansion Act; it said Fluad, its main U.S. Seqirus product, is made in the United Kingdom, where the tariff rate was then 10% and expected to fall to zero, with any tariff impacts effective Sept. 29, 2026.
The downside scenario is plain: the buyback may ease trading pressure without changing demand. If voluntary flu shots among service members replace mandatory volumes only partly, and if broader U.S. vaccine uptake stays weak, Seqirus remains exposed while CSL still has to show progress in plasma, Vifor and cost-cutting.
The next signal is unlikely to be a single daily filing. Investors will track whether CSL keeps buying as shares sit near long-term lows, whether U.S. flu orders recover, and whether Naylor can turn the transformation program into earnings rather than another reset.
